• Beta Bionics Chief Commercial Officer Mark Hopman sold 370 shares of common stock on Oct. 1, 2026.
• Shares sold at a weighted average price of $18.96, within a $18.96 to $19.9599 range.
• Holdings fell to 56,109 shares following the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beta Bionics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002048497-26-000018), on October 05, 2026, and is solely responsible for the information contained therein.